Current cardiovascular medical devices, such as grafts and stents, exhibit poor clinical outcomes that need revision surgery due to the propensity of these materials to induce thrombosis and restenosis. Our work has demonstrated that coatings of vascular proteoglycans promote endothelialisation whilst inhibiting smooth muscle cell proliferation, platelet adhesion and activation. Some of these coatings improved endothelialisation of vascular grafts by 36% and reduced thrombosis by 65% over the current materials in an ovine carotid model over 6 weeks. These studies are promising; however the yield of naturally derived proteoglycans limits the clinical translation of this work. The focus of this project to further knowledge of how to bioengineer proteoglycans and develop next-generation vascular biomaterials composed of bioengineered proteoglycans that modulate the binding of environmental cues to support functional vasculature for improved medical device performance.
Bioengineering biomimetic biomaterials